Our work confirms the findings concerning an acquired resistance to paclitaxel after RASSF1A depletion (already observed in primary ovarian cancer cell models) [55], while elucidating how the RASSF1A loss could lead to a decreased gemcitabine effectiveness. This evidence concerns the gene RASSF1 and ovarian carcinoma.